HLHS stands for hypoplastic left heart syndrome, a severe congenital heart defect in which left-sided cardiac structures are underdeveloped and cannot adequately support systemic circulation. Newborns typically require staged surgical palliation and lifelong cardiology follow-up. Without treatment, the condition is fatal early in life.
Longeveron Inc. announced Phase 2b clinical trial results published in Cell Stem Cell showing laromestrocel improved physical condition in patients with age-related frailty after nine months compared to placebo.
Longeveron Inc. appointed Stephen H. Willard as CEO effective February 11, 2026, replacing interim CEO Than Powell. The appointment comes as the company expects top-line results from its pivotal Phase 2b trial for Hypoplastic Left Heart Syndrome in Q3 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03525418 |
Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
